Replimune reels in $30 mln Series A

By Iris Dorbian — 5 months ago

UK-based Replimune, a developer of oncolytic immunotherapy, has secured $30 million in Series A funding. Atlas Venture led the round with participation from return backers Forbion Capital Partners and Omega Funds. In addition to the funding, Jason Rhodes of Atlas, Otello Stampacchia of Omega and Sander Slootweg of Forbion have been added to Replimune’s board.

Continue

Forbion FCF II Co-invest Fund I closes at $84 mln

By Luisa Beltran — 5 months ago

Forbion Capital Partners said it closed its Forbion Capital Fund II Co-invest Fund I with 75 million Euros (US$84 million). The Co-Invest fund was set up to allow Forbion’s existing LPs to back later-stage, de-risked companies within the existing FCF II portfolio with additional (growth) capital. The pool will invest in up to six existing FCF II portfolio companies, alongside FCF II. Forbion is a Life Sciences venture capital firm with offices in Naarden, The Netherlands

Continue

Forbion Capital invests in Sanifit’s $41 mln round

By Luisa Beltran — 5 months ago

Sanifit raised 36.6 million Euros (US$41 million) in a Series C round of financing. Forbion Capital Partners took part in the round as well as Ysios Capital, Lundbeckfond Ventures, Gilde Healthcare, Edmond de Rothschild Investment Partners, “la Caixa” and Baxter Healthcare. Existing shareholders also supported the series C round. Sanifit is a Spanish clinical-stage biopharmaceutical company.

Continue

Rigontec GmbH raises $5.3 mln in Series A

By Luisa Beltran — 11 months ago

Rigontec GmbH said Tuesday it raised 4.8 million Euros (about US$5.3 mln) in a second closing of a series A round from Forbion Capital Partners and Sunstone Capital. Rigontec said total Series A funding was 14.25 million Euros (US$15.7 mln). Bonn, Germany-based Rigontech is a biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

Continue

Forbion Capital sells PneumRx

By Luisa Beltran — 1 year ago

Forbion Capital Partners has sold PneumRx to BTG. Cash consideration was $230 million and up to $245 million in performance related future milestone payments.PneumRx is a interventional pulmonology business that makes and distributes the RePneu Coil System, which aims to treat advanced emphysema.

Continue

Exosome Diagnostics nabs $27 mln

By Iris Dorbian — 2 years ago

Exosome Diagnostics said Tuesday that it has closed $27 million in Series B financing. New investors QIAGEN and Arcus Ventures led the round with participation from Tiger Partners, CD Ventures, Monashee Capital, NGN Capital and Forbion Capital Partners. Leerink Swann served as financial advisor and placement agent to Exosome on the transaction. In conjunction with the funding, Dr. Steven Soignet, general partner at Arcus Ventures, has been added to Exosome’s board of directors. Exosome is a developer of molecular diagnostic tests.

Continue

RuiYi and arGEN-X Announce License Agreement

By Angela Sormani — 3 years ago

arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

Continue

Astley-Sparke Joins Forbion Capital

By Luisa Beltran — 3 years ago

Philip Astley-Sparke has joined Forbion Capital Partners as a venture partner based in Boston. He had been BioVex’s president and CEO since 2005. Once Amgen acquired BioVex in March 2011, Astley-Sparke served as VP and GM of Amgen until the following December. PRESS RELEASE Forbion Capital Partners today announced Philip Astley-Sparke, the former President and CEO […]

Continue

Promedior Appoints President and CEO

By Angela Sormani — 4 years ago

Promedior, a clinical stage biotechnology company developing biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn as president and chief executive officer. In March, the company announced the closing of a Series D financing round led by Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare […]

Continue

Promedior Raises $21.5 Million

By Angela Sormani — 4 years ago

Promedior, a clinical stage biotechnology company has raised $21.5M in a first closing of a Series D financing round. The financing was led by a new investor, Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This […]

Continue

Promedior Inks $21.5M

By Staff Report — 4 years ago

Malvern, Penn.-based Promedior Inc., a clinical stage biotechnology company developing therapeutics for fibroproliferative diseases, has held a $21.5 million first closing of its Series D round.  New investor Fibrotec Ventures led the round, which included existing shareholders Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This new round […]

Continue

arGEN-X Inks $37M Series B

4 years ago

arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.

Continue

CircuLite Raises $30m for Series D

By Angela Sormani — 4 years ago

CircuLite, a developer of a surgically implanted blood pump for long-term use in heart failure patients, has raised $30 million for its oversubscribed Series D financing round. The round was led by new investor, MacAndrews & Forbes Holdings, and Netherlands-based Forbion Capital Partners, a founding VC of CircuLite and the largest investor in the company. […]

Continue

Oxyrane Adds $26.5M

4 years ago

Oxyrane UK Ltd., a biopharmaceutical company based in The Netherlands, has closed on $26.5 million in a equity round of funding. Investors include Forbion Capital Partners, Morningside Groups and New Science Ventures. Sander Slootweg of Forbion and Gerald Chan of Morningside Group have joined the company’s board. Oxyrane is developing enzyme replacement therapies to treat rare inheritied diseases.

Continue

AM-Pharma Raises $40M Series D

4 years ago

AM-Pharma NV, a Dutch developer of Alkaline Phosphatase for treatment of severe inflammatory diseases, has closed on 29.2 million euro ($39.8 million) in a Series D financing round led by Ysios Capital Partners. Kurma Life Science Partners co-led the round, which included participation from the venture arms of two global Healthcare companies, Abbott and Shire. Venture funds BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital also joined in the round.

Continue